Modality
Vaccine
MOA
EZH2i
Target
C5
Pathway
Lipid Met
PsoriasisBCCT2D
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
~Nov 2020
→ ~Feb 2022
NDA/BLA
May 2022
→ Mar 2031
NDA/BLACurrent
NCT04743209
202 pts·Psoriasis
2022-05→2031-03·Terminated
202 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-285.0y awayPh3 Readout· Psoriasis
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2031-03-28 · 5.0y away
Psoriasis
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04743209 | NDA/BLA | Psoriasis | Terminated | 202 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-1232 | Halozyme | Approved | C5 |